American officials decided to remove about 60 million doses of Vacicne Covid-19 of Johnson & Johnson because they could be contaminated during the production process.

The US Food and Drug Administration (FDA) warns management agencies that cannot guarantee Emergent Biosolutions, Johnson & Johnson's Johnson & Johnson's vaccine production partner, well comply with production processes.

FDA has not decided to reopen the Factory of Emergent Biosolutions after two months closed due to concerns from the management agency, sources on May 11 said.

FDA for many weeks seeking to handle at least 170 million doses of vaccines suspended from circulating after detecting a large offense related to production at Emergent Biosolutions factory in Baltimore, Maryland.

Over 100 million doses of Johnson & Johnson vaccine and at least 70 million doses of Astrazeneca vaccine are stopped after Emergent Biosolutions to detect factory workers mixing two types of vaccines.

American officials then suspend the factory's operations, requires this facility to stop production of Astrazeneca vaccines and Directive Johnson & Johnson directly control its product production.

Emergent's production facility in Baltimore Biosolutions in Maryland, USA.

Johnson & Johnson's Vaccine Covid-19 is identified as a potential product that changes the pandemic situation due to just a nose and is particularly useful for vulnerable communities.

However, the loss of 60 million doses of Johnson & Johnson's vaccine influenced the plan of the US President Joe Biden to distribute Vaccine Covid-19 to other countries that suffer a pandemic.

After going to England to attend the G7 Summit, Biden announced the new vaccine supply.

FDA's move is to believe in Johnson & Johnson and Emergent Biosolutions.

US regulators are continuing to question the ability to comply with Emergent BioSolutions production standards, after the company is paid hundreds of millions from the government to serve the production of Covid-19 vaccines.